60 Degrees Pharmaceuticals (SXTP) Net Margin (2022 - 2026)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Net Margin of 1289.49% for Q1 2026, down 6381.0% year-over-year from 20.53% in Q1 2025, and down 299.4% quarter-over-quarter from 322.86% in Q4 2025.
60 Degrees Pharmaceuticals (SXTP) Net Margin (2022 - 2026) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Net Margin for 5 consecutive years, with 1289.49% the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Margin fell 6381.0% year-over-year to 1289.49%; the TTM figure through Mar 2026 stood at 709.32% (up 90520.0% YoY), while the FY2025 annual figure was 687.12%, up 70045.0% from the prior year.
- Net Margin eased to 1289.49% in Q1 2026 per SXTP's latest filing, from 322.86% in the prior quarter.
- Across five years, Net Margin topped out at 7992.11% in Q3 2023 and bottomed at 15148.79% in Q1 2023.
- Historically, Net Margin has averaged 1390.15% across 5 years, with a median of 864.15% in 2022.
- On a YoY basis, Net Margin climbed as much as 1544091 bps in 2024 and fell as far as 967139 bps in 2024.
- 60 Degrees Pharmaceuticals' Net Margin stood at 864.15% in 2022, then advanced by 12 bps to 764.18% in 2023, then retreated by 18 bps to 902.08% in 2024, then surged by 64 bps to 322.86% in 2025, then sank by 299 bps to 1289.49% in 2026.
- Business Quant data shows SXTP's Net Margin at 1289.49% in Q1 2026, 322.86% in Q4 2025, and 529.48% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.03 Bn | 131.18 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 64.93 Bn | 59.75 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 57.93 Bn | 52.80 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 41.95 Bn | 36.86 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 31.51 Bn | 28.20 Bn | 992.69 Mn | 12.74% |
| 7 | BioNTech SE | 28.00 Bn | 9.60 Bn | 668.28 Mn | -16.51% |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -3.12% |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 12.09% |
| 10 | 60 Degrees Pharmaceuticals | 3.00 Mn | 1.98 Mn | 56,798.00 | -1,089.76% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,289.49% |
| Dec 31, 2025 | -322.86% |
| Sep 30, 2025 | -529.48% |
| Jun 30, 2025 | -1,718.91% |
| Mar 31, 2025 | -1,225.67% |
| Dec 31, 2024 | -902.08% |
| Sep 30, 2024 | -1,679.28% |
| Jun 30, 2024 | -3,430.77% |
| Mar 31, 2024 | 292.12% |
| Dec 31, 2023 | -764.18% |
| Sep 30, 2023 | 7,992.11% |
| Jun 30, 2023 | -834.81% |
| Mar 31, 2023 | -15,148.79% |
| Sep 30, 2022 | -864.15% |
| Jun 30, 2022 | -426.07% |